Septerna's Chief People Officer Sold Nearly 12,000 Company Shares. What Does That Mean for Investors?
By
[email protected] (Robert Izquierdo)
3d agoen
Source
BarsSepterna's Chief People Officer Sold Nearly 12,000 Company Shares. What Does That Mean for Investors?fool.comSepterna, a clinical-stage biotech focused on GPCR-targeted therapies, reported significant insider selling in its latest SEC filing.
You might also wanna read
FDA Drug Regulator Accused of Targeting Former Business Associate's Pharmaceutical Company
The article discusses a scandal at the FDA involving a top drug regulator who allegedly used his position to target a former business associ
arstechnica.com·8mo ago
Biotech venture capital roundup: Osanni Bio leads with $190M Series B
A roundup of recent venture capital financings in the biotech sector, headlined by Osanni Bio's $190 million Series B round to fund drug can
pharmaphorum.com·13d ago
How Direct Digital Investing can pave the way to the Stock Market
Invesdor·7d ago
Biotech NRx to sell new shares to fund growth and operations
stocktitan.net·1mo ago
Allotera Therapeutics closes $35M financing
thefly.com·6h ago
Recent moves of note in and around the biotech and pharma industries
nature.com·12d ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.